magnolol has been researched along with Colitis Gravis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, C; Gu, H; Li, J; Wang, X; Xian, J; Zhang, C; Zhang, H; Zhang, J | 1 |
| Cao, Y; Gu, C; He, Y; Li, S; Li, Y; Liu, J; Lu, X; Shen, P; Zhang, N; Zhang, Z; Zhu, K | 1 |
2 other study(ies) available for magnolol and Colitis Gravis
| Article | Year |
|---|---|
Oral Core-Shell Nanoparticles Embedded in Hydrogel Microspheres for the Efficient Site-Specific Delivery of Magnolol and Enhanced Antiulcerative Colitis Therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biphenyl Compounds; Cell Line, Tumor; Chondroitin Sulfates; Colitis, Ulcerative; Colon; Dextran Sulfate; Drug Carriers; Drug Liberation; Humans; Hydrogels; Lignans; Male; Mice, Inbred ICR; Microspheres; Nanoparticles; Occludin; Zein; Zonula Occludens-1 Protein | 2021 |
Magnolol treatment attenuates dextran sulphate sodium-induced murine experimental colitis by regulating inflammation and mucosal damage.
Topics: Animals; Biphenyl Compounds; Cecum; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Gastrointestinal Agents; Inflammation; Inflammation Mediators; Intestinal Mucosa; Lignans; Male; Mice; Mice, Inbred C57BL; Occludin; PPAR gamma; Weight Loss | 2018 |